Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) down 0.1%.
Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.